CervoMed Inc. presented groundbreaking findings at the 2026 AAN Annual Meeting, demonstrating that neflamapimod may reverse atrophy in the basal forebrain of patients with dementia with Lewy bodies (DLB). This placebo-controlled MRI analysis from the RewinD-LB Phase 2b trial revealed significant increases in basal forebrain volume and functional connectivity, suggesting potential restoration of synaptic function and cellular integrity in this critical brain region.

The significance of these findings lies in their correlation with preclinical data indicating that early-stage neurodegenerative processes in the basal forebrain may be reversible. Specifically, patients treated with neflamapimod showed a 10.9 mm³ increase in right basal forebrain volume compared to a decrease of 13.3 mm³ in the placebo group (p=0.022). Additionally, improvements in functional connectivity between the basal forebrain and the default mode network were observed, which is crucial given the cholinergic deficits associated with DLB. These results underscore neflamapimod’s potential to address the underlying pathophysiology of DLB, a condition currently without approved treatments.

The implications for the field are substantial. The demonstrated ability of neflamapimod to elicit structural and functional changes in the basal forebrain not only supports its therapeutic potential but also highlights the utility of MRI as a sensitive biomarker for assessing treatment effects in neurodegenerative diseases. This could expedite drug development timelines and shift research paradigms towards targeting early-stage neurodegeneration in DLB and similar disorders. CervoMed plans to leverage these insights in its upcoming Phase 3 trial, aiming to further validate neflamapimod’s efficacy and establish a new standard in the treatment of DLB.

Source: globenewswire.com